Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

July 1, 2008

Primary Completion Date

March 12, 2021

Study Completion Date

March 12, 2021

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Etoposide, carboplatin, ifosfamide

Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.

DRUG

Rituximab, Ifosfamide, Etoposide, Carboplatin

It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.

DRUG

Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine

"It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital."

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Columbia University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00712582 - Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma | Biotech Hunter | Biotech Hunter